

Martina Uttenreuther-Fischer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/281656/publications.pdf>

Version: 2024-02-01

248
papers

15,896
citations

47006

47
h-index

19749

117
g-index

254
all docs

254
docs citations

254
times ranked

13876
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. <i>New England Journal of Medicine</i> , 2017, 376, 2147-2159.	27.0	1,228
2	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 393, 156-167.	13.7	1,153
3	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	27.0	1,143
4	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 9-20.	27.0	854
5	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 1506-1517.	10.7	767
6	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2021, 398, 759-771.	13.7	642
7	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	1.6	614
8	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 689-699.	10.7	595
9	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1143-1154.	27.0	474
10	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1688-1700.	10.7	451
11	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2020, 21, 519-530.	10.7	441
12	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. <i>Lancet Oncology, The</i> , 2014, 15, 1137-1146.	10.7	382
13	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1360-1372.	10.7	377
14	Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 743-754.	10.7	372
15	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. <i>JAMA Oncology</i> , 2019, 5, 546.	7.1	366
16	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With 2 HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3138-3149.	1.6	355
17	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1557.	7.1	242
18	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 573.	7.1	217

#	ARTICLE	IF	CITATIONS
19	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology, The</i> , 2020, 21, 1283-1295.	10.7	213
20	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1057-1065.	2.5	183
21	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology, The</i> , 2017, 18, 323-335.	10.7	173
22	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancerâ€”The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	1.6	153
23	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2020, 21, 763-775.	10.7	144
24	Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2-2.	1.6	136
25	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2016, 17, 357-366.	10.7	125
26	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2â€”Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3626-3633.	1.6	118
27	How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. <i>ESMO Open</i> , 2018, 3, e000357.	4.5	112
28	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2015, 16, 1700-1710.	10.7	108
29	Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 1856-1864.	1.6	100
30	Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3065-3076.	1.6	97
31	Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology, The</i> , 2019, 20, 1750-1759.	10.7	86
32	Diagnostic accuracy and safety of ^{18}F -[18F]fluoro- $^{17}\beta$ -oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. <i>Lancet Oncology, The</i> , 2019, 20, 546-555.	10.7	85
33	Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 330-334.	0.6	84
34	HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 237-250.	2.5	84
35	Breast Cancer Recurrence in the Nipple-Areola Complex After Nipple-Sparing Mastectomy With Immediate Breast Reconstruction for Invasive Breast Cancer. <i>JAMA Surgery</i> , 2019, 154, 1030.	4.3	75
36	Pretreatment albumin level predicts survival in head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2017, 127, E437-E442.	2.0	73

#	ARTICLE	IF	CITATIONS
37	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1002-1002.	1.6	71
38	Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 2336-2342.	5.1	69
39	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. <i>JAMA Oncology</i> , 2021, 7, 1873.	7.1	66
40	HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant+adjuvant trastuzumab after 2 years of treatment-free follow-up. <i>European Journal of Cancer</i> , 2016, 62, 62-75.	2.8	64
41	Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. <i>Cancer</i> , 2015, 121, 2612-2617.	4.1	63
42	Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.. <i>Journal of Clinical Oncology</i> , 2017, 35, 556-556.	1.6	60
43	Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling. <i>Breast Cancer Research</i> , 2014, 16, 479.	5.0	58
44	Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. <i>Cellular and Molecular Immunology</i> , 2015, 12, 87-95.	10.5	57
45	Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer. <i>European Journal of Cancer</i> , 2019, 116, 98-106.	2.8	54
46	Pretreatment depression as a prognostic indicator of survival and nutritional status in patients with head and neck cancer. <i>Cancer</i> , 2016, 122, 131-140.	4.1	53
47	Raloxifene Induces Autophagy-Dependent Cell Death in Breast Cancer Cells via the Activation of AMP-Activated Protein Kinase. <i>Molecules and Cells</i> , 2015, 38, 138-144.	2.6	51
48	A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. <i>International Journal of Cancer</i> , 2018, 143, 3240-3247.	5.1	46
49	Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: High rate of systemic failure warrants targeted therapy. <i>Oral Oncology</i> , 2014, 50, e64-e66.	1.5	44
50	Expression of FOXM1 and related proteins in breast cancer molecular subtypes. <i>International Journal of Experimental Pathology</i> , 2016, 97, 170-177.	1.3	43
51	Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). <i>Radiotherapy and Oncology</i> , 2016, 118, 244-250.	0.6	43
52	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2019, 14, 591-601.	3.6	43
53	Long-term Oncologic Outcomes of Immediate Breast Reconstruction vs Conventional Mastectomy Alone for Breast Cancer in the Setting of Neoadjuvant Chemotherapy. <i>JAMA Surgery</i> , 2020, 155, 1142.	4.3	41
54	A Randomized Feasibility Study of ¹⁸ F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 563-568.	5.0	40

#	ARTICLE	IF	CITATIONS
55	Randomized Phase 2 Trial of S1 and Oxaliplatin-Based Chemoradiotherapy With or Without Induction Chemotherapy for Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 489-496.	0.8	39
56	Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13â€“01). <i>BMC Cancer</i> , 2020, 20, 813.	2.6	39
57	Clinical Characteristics and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck. <i>Laryngoscope</i> , 2013, 123, 1430-1438.	2.0	38
58	Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1031-1040.	2.5	38
59	RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4012-4012.	1.6	38
60	Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 377-386.	2.5	38
61	Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4010-4010.	1.6	38
62	Prevalence and clinical significance of cancer cachexia based on time from treatment in advanced-stage head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 716-723.	2.0	37
63	Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. <i>Thyroid</i> , 2017, 27, 1135-1141.	4.5	37
64	Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. <i>Journal of Global Oncology</i> , 2019, 5, 1-19.	0.5	34
65	Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01). <i>Cancer Research and Treatment</i> , 2019, 51, 43-52.	3.0	34
66	Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients. <i>Breast</i> , 2016, 28, 67-72.	2.2	33
67	Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 565-575.	2.3	32
68	Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. , 2020, 8, e000342.		32
69	Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 526-526.	1.6	32
70	Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 565-576.	2.5	32
71	An Introduction to a Head and Neck Cancer-Specific Frailty Index and Its Clinical Implications in Elderly Patients: A Prospective Observational Study Focusing on Respiratory and Swallowing Functions. <i>Oncologist</i> , 2016, 21, 1091-1098.	3.7	31
72	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , 2021, 26, e1327-e1338.	3.7	31

#	ARTICLE	IF	CITATIONS
73	A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.. Journal of Clinical Oncology, 2020, 38, 1023-1023.	1.6	29
74	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Medicine, 2016, 13, e1002136.	8.4	28
75	Three-Year Follow-Up and Responseâ€“Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). Clinical Cancer Research, 2022, 28, 3277-3286.	7.0	27
76	Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma. Clinical Cancer Research, 2021, 27, 5272-5279.	7.0	26
77	Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2019, 37, 1013-1013.	1.6	26
78	Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma. BMC Cancer, 2016, 16, 42.	2.6	25
79	Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2018, 36, 1008-1008.	1.6	24
80	Synchronous second primary cancers in patients with squamous esophageal cancer: clinical features and survival outcome. Korean Journal of Internal Medicine, 2016, 31, 253-259.	1.7	24
81	Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience. Cancer Chemotherapy and Pharmacology, 2013, 72, 201-207.	2.3	23
82	Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. European Journal of Cancer, 2017, 86, 385-393.	2.8	23
83	A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). Anticancer Research, 2019, 39, 5123-5133.	1.1	23
84	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with ¹³¹I-refractory differentiated thyroid cancer (SELECT).. Journal of Clinical Oncology, 2014, 32, LBA6008-LBA6008.	1.6	23
85	Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. Breast Cancer Research and Treatment, 2011, 128, 171-177.	2.5	22
86	Recurrence Outcomes After Nipple-Sparing Mastectomy and Immediate Breast Reconstruction in Patients with Pure Ductal Carcinoma In Situ. Annals of Surgical Oncology, 2020, 27, 1627-1635.	1.5	22
87	End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1020-1020.	1.6	22
88	Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients. Clinical Pharmacology in Drug Development, 2013, 2, 336-341.	1.6	21
89	Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer. Annals of Surgery, 2022, 275, 467-476.	4.2	21
90	Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, 1003-1003.	1.6	21

#	ARTICLE	IF	CITATIONS
91	Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2022, 8, 1190.	7.1	21
92	p16 immunohistochemistry alone is a better prognosticator in tonsil cancer than human papillomavirus in situ hybridization with or without p16 immunohistochemistry. <i>Acta Oto-Laryngologica</i> , 2013, 133, 297-304.	0.9	20
93	Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers. <i>PLoS ONE</i> , 2015, 10, e0137885.	2.5	20
94	Effect of Metformin on Progression of Head and Neck Cancers, Occurrence of Second Primary Cancers, and Cause-Specific Survival. <i>Oncologist</i> , 2015, 20, 546-553.	3.7	20
95	Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 685-695.	2.3	20
96	Pretreatment quality of life as a prognostic factor for early survival and functional outcomes in patients with head and neck cancer. <i>Quality of Life Research</i> , 2016, 25, 165-174.	3.1	19
97	Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. <i>Npj Breast Cancer</i> , 2018, 4, 19.	5.2	19
98	Radiation-induced esophageal strictures treated with fluoroscopic balloon dilation: clinical outcomes and factors influencing recurrence in 62 patients. <i>Acta Radiologica</i> , 2018, 59, 313-321.	1.1	18
99	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	7.0	18
100	Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 655-663.	2.3	17
101	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). <i>Breast Cancer Research and Treatment</i> , 2015, 152, 77-85.	2.5	17
102	MRI-based 3D-printed surgical guides for breast cancer patients who received neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2019, 9, 11991.	3.3	17
103	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	5.0	17
104	Characteristics of metastatic brachial plexopathy in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 1913-1918.	2.2	17
105	Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Cancer Research and Treatment</i> , 2022, 54, 505-516.	3.0	17
106	Oncologic Safety of Nipple-Sparing Mastectomy in Patients with Breast Cancer and Tumor-to-Nipple Distance: A Matched Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 4284-4291.	1.5	16
107	IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer (BC). <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1117-TPS1117.	1.6	16
108	Claudin 1, 3, 4, and 7 expression in triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1070-1070.	1.6	16

#	ARTICLE	IF	CITATIONS
109	Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.. Journal of Clinical Oncology, 2020, 38, 6503-6503.	1.6	15
110	Importance of FOXP3 in prognosis and its relationship with p16 in tonsillar squamous cell carcinoma. Anticancer Research, 2013, 33, 5667-73.	1.1	15
111	In vitro Priming of Myeloma Antigen-specific Allogeneic Donor T Cells with Idiotype Pulsed Dendritic Cells. Leukemia and Lymphoma, 2003, 44, 1201-1208.	1.3	14
112	Prognostic value of neutrophil-to-lymphocyte ratio in older patients with head and neck cancer. Journal of Geriatric Oncology, 2020, 11, 417-422.	1.0	14
113	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. Cancer Research and Treatment, 2021, 53, 671-677.	3.0	14
114	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 5818-5827.	7.0	14
115	A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10). Tj ETQq1 1 0.784314 rgBt4/Overlo	1.0	14
116	The Feasibility of 18F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer. Nuclear Medicine and Molecular Imaging, 2012, 46, 57-64.	1.0	13
117	Ibuprofen sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage. International Journal of Biochemistry and Cell Biology, 2017, 83, 47-55.	2.8	13
118	Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up. International Journal of Clinical Oncology, 2018, 23, 52-58.	2.2	13
119	Locoregional recurrence following nipple-sparing mastectomy with immediate breast reconstruction: Patterns and prognostic significance. European Journal of Surgical Oncology, 2021, 47, 1309-1315.	1.0	13
120	No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-Conserving Surgery. Cancer Research and Treatment, 2018, 50, 275-282.	3.0	13
121	Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study. Journal of Breast Cancer, 2018, 21, 70.	1.9	12
122	Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer. Anticancer Research, 2019, 39, 3111-3119.	1.1	12
123	Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer. Annals of Surgical Oncology, 2019, 26, 2166-2174.	1.5	12
124	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3359-3369.	2.5	12
125	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. Clinical Cancer Research, 2021, 27, 6156-6163.	7.0	12
126	Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.. Journal of Clinical Oncology, 2020, 38, 1036-1036.	1.6	12

#	ARTICLE	IF	CITATIONS
127	Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2018, 92, 69-76.	2.8	11
128	Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 17466.	3.3	11
129	Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1012-1024.	3.0	11
130	Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1113-TPS1113.	1.6	11
131	Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. <i>Head and Neck</i> , 2001, 23, 223-229.	2.0	10
132	Predictive factors for long-term survival in head and neck squamous cell carcinoma patients with distant metastasis after initial definitive treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 295-304.	2.5	10
133	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018, 103, 127-136.	2.8	10
134	A Propensity Score-matched Analysis of Long-term Oncologic Outcomes After Nipple-sparing Versus Conventional Mastectomy for Locally Advanced Breast Cancer. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	10
135	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+ metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). <i>British Journal of Cancer</i> , 2019, 121, 985-990.	6.4	9
136	Oncologic Outcomes of Nipple-sparing Mastectomy and Immediate Reconstruction After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, e1196-e1201.	4.2	9
137	BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6008-6008.	1.6	9
138	Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study. <i>Oncotarget</i> , 2018, 9, 3875-3886.	1.8	9
139	Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1373-1381.	3.0	9
140	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1000-1000.	1.6	9
141	Effect Modification of Hormonal Therapy by p53 Status in Invasive Breast Cancer. <i>Journal of Breast Cancer</i> , 2013, 16, 386.	1.9	8
142	Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 995-1003.	2.3	8
143	Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. <i>Future Oncology</i> , 2019, 15, 2489-2501.	2.4	8
144	Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 204-204.	1.6	8

#	ARTICLE	IF	CITATIONS
145	A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1014-1014.	1.6	8
146	Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II. Journal of Breast Cancer, 2015, 18, 356.	1.9	7
147	Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS. Lancet Oncology, The, 2017, 18, e638.	10.7	7
148	Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. British Journal of Cancer, 2018, 118, 344-352.	6.4	7
149	Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade. Clinical Breast Cancer, 2020, 20, 25-32.	2.4	7
150	Clinical effectiveness and safety of self-expanding metal stent placement following palliative chemotherapy in patients with advanced esophageal cancer. Abdominal Radiology, 2020, 45, 563-570.	2.1	7
151	Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES. Breast Cancer Research and Treatment, 2021, 188, 77-89.	2.5	7
152	Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: A retrospective study. Radiotherapy and Oncology, 2021, 162, 112-118.	0.6	7
153	Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Cancer Research and Treatment, 2017, 49, 423-429.	3.0	7
154	Role of Esophagectomy after Chemoradiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma: A Comparative Analysis Stratified by Clinical Response to Chemoradiation Therapy. Cancer Research and Treatment, 2021, , .	3.0	7
155	Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Cancers, 2021, 13, 6267.	3.7	7
156	A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15031.	4.1	6
157	The role of postoperative radiotherapy after primary tumor resection in patients with de novo stage IV breast cancer. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 495-505.	1.1	6
158	Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).. Journal of Clinical Oncology, 2019, 37, 6081-6081.	1.6	6
159	A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer. Cancer Research and Treatment, 2015, 47, 406-415.	3.0	6
160	S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?. Expert Review of Anticancer Therapy, 2010, 10, 659-662.	2.4	5
161	Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial. Investigational New Drugs, 2014, 32, 753-761.	2.6	5
162	Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: Results from 5 years follow-up on Asia-Pacific Breast Initiative-I. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 125-132.	1.1	5

#	ARTICLE	IF	CITATIONS
163	Risk factors for competing non-cancer mortality after definitive treatment for advanced-stage head and neck cancer. <i>Oral Diseases</i> , 2018, 24, 1217-1225.	3.0	5
164	Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG Tj ETQq0 0 0 r gBT /Overlock 10 T	0.2	5
165	Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 315-324.	2.5	5
166	Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 168-168.	1.6	5
167	Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. <i>European Journal of Cancer</i> , 2021, 144, 341-350.	2.8	5
168	Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. <i>Cancer Research and Treatment</i> , 2021, 53, 1084-1095.	3.0	5
169	Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01). <i>Cancer Research and Treatment</i> , 2022, 54, 109-117.	3.0	5
170	Final results of the randomized phase 2 <sc>LEO</sc> trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, <sc>HER2</sc>-negative metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 917-924.	5.1	5
171	Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 469-477.	3.0	5
172	The Association between Herpes Zoster and Increased Cancer Risk: A Nationwide Population-Based Matched Control Study. <i>Current Oncology</i> , 2021, 28, 2720-2730.	2.2	5
173	Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting. <i>BMC Proceedings</i> , 2021, 15, 15.	1.6	5
174	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1527-1539.	3.0	5
175	Abstract OT2-11-01: EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigator's choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. <i>Cancer Research</i> , 2022, 82, OT2-11-01-OT2-11-01.	0.9	5
176	Prognostic factors in patients with head and neck squamous cell carcinoma with cN3 neck disease: a retrospective case-control study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 117, 178-185.	0.4	4
177	Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors – proceedings from breast cancer expert group meeting. <i>Chinese Clinical Oncology</i> , 2020, 9, 61-61.	1.2	4
178	Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. <i>Journal of Breast Cancer</i> , 2021, 24, 359.	1.9	4
179	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4150-TPS4150.	1.6	4
180	Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4032-4032.	1.6	4

#	ARTICLE	IF	CITATIONS
181	Clinical implications of endoscopic ultrasonography non-traversability in patients with locoregional esophageal cancer receiving multimodality therapy. Korean Journal of Internal Medicine, 2017, 32, 443-451.	1.7	4
182	RNA Sequencing for Elucidating an Intronic Variant of Uncertain Significance (<i>SDHD</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 T	2.5	4
183	Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110619.	3.2	4
184	CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience. Journal of Breast Cancer, 2022, 25, 49.	1.9	4
185	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. Cancer Research, 2022, 82, PD8-01-PD8-01.	0.9	4
186	Translation and validation of Korean Functional Assessment of Cancer Therapy-Esophageal (FACT-E) scale with squamous cell carcinoma and chemoradiation-only patients. Quality of Life Research, 2012, 21, 1451-1457.	3.1	3
187	Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen. Journal of Breast Cancer, 2019, 22, 387.	1.9	3
188	Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2â€™Negative Advanced Breast Cancer. Journal of Breast Cancer, 2021, 24, 97.	1.9	3
189	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer. Scientific Reports, 2021, 11, 10510.	3.3	3
190	Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2021, 39, 517-517.	1.6	3
191	Patient-reported outcomes (PROs) from TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physicianâ€™s choice (TPC) in patients with pretreated HER2-positive advanced breast cancer.. Journal of Clinical Oncology, 2014, 32, 153-153.	1.6	3
192	Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).. Journal of Clinical Oncology, 2015, 33, 610-610.	1.6	3
193	Safety of eribulin in Korean patients with metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, e12031-e12031.	1.6	3
194	LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, TPS1111-TPS1111.	1.6	3
195	Long-Term Survival and Tumor Recurrence in Patients with Superficial Esophageal Cancer after Complete Non-Curative Endoscopic Resection: A Single-Center Case Series. Clinical Endoscopy, 2018, 51, 470-477.	1.5	3
196	Preliminary safety and efficacy of GX-17, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).. Journal of Clinical Oncology, 2020, 38, 1072-1072.	1.6	3
197	Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. Scientific Reports, 2022, 12, 7858.	3.3	3
198	Phase 1b/2 study of GX-17 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.. Journal of Clinical Oncology, 2022, 40, 1081-1081.	1.6	3

#	ARTICLE	IF	CITATIONS
199	Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia. <i>Future Oncology</i> , 2019, 15, 3243-3253.	2.4	2
200	Impact of sequential lines of palliative chemotherapy in patients with recurrent/metastatic esophageal squamous cell carcinoma: A retrospective analysis of 107 patients at a single center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e53-e62.	1.1	2
201	A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy. <i>Investigational New Drugs</i> , 2020, 38, 866-873.	2.6	2
202	Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 583-592.	2.5	2
203	Neratinib+capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and 2 prior HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 449-458.	1.5	2
204	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. <i>Journal of Clinical Oncology</i> , 2021, 39, 518-518.	1.6	2
205	First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3107-3107.	1.6	2
206	The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial. <i>Ecological Management and Restoration</i> , 2021, , .	0.4	2
207	Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib.. <i>Journal of Clinical Oncology</i> , 2014, 32, 605-605.	1.6	2
208	Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1074-1074.	1.6	2
209	COLET (NCT02322814): A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS1100-TPS1100.	1.6	2
210	SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1040-1040.	1.6	2
211	Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen. <i>Journal of Breast Cancer</i> , 2020, 23, 553.	1.9	2
212	Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11579-e11579.	1.6	2
213	Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01). <i>Korean Journal of Internal Medicine</i> , 2022, 37, 190-200.	1.7	2
214	Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories. <i>Journal of Breast Cancer</i> , 0, 25, .	1.9	2
215	Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study. <i>Current Therapeutic Research</i> , 2007, 68, 193-204.	1.2	1
216	Is asymptomatic surveillance beneficial after standard treatment? A 10-year survival analysis of recurrent BC patients by detection method of recurrence. <i>Breast Journal</i> , 2020, 26, 556-559.	1.0	1

#	ARTICLE	IF	CITATIONS
217	Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. <i>Anticancer Research</i> , 2020, 40, 5883-5893.	1.1	1
218	Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 254-255.	1.6	1
219	Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 665426.	2.8	1
220	A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6597-TPS6597.	1.6	1
221	Metastatic Tumors to the Breast from Extramammary Malignancies. <i>Korean Journal of Pathology</i> , 2010, 44, 70.	1.3	1
222	Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 1745-1758.	2.8	1
223	Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespi in first-line treatment of women with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS665-TPS665.	1.6	1
224	Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6024-6024.	1.6	1
225	Prognostic significance of lymph node ratio after neoadjuvant chemoradiation therapy for esophageal squamous cell carcinoma. <i>Radiation Oncology Journal</i> , 2020, 38, 244-252.	1.5	1
226	338â€¦Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study. , 2021, 9, A364-A364.		1
227	261â€¦Association of T-cellâ€œinflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180. , 2020, , .		1
228	Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. <i>Journal of Clinical Oncology</i> , 2022, 40, 279-279.	1.6	1
229	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS370-TPS370.	1.6	1
230	Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 268-268.	1.6	1
231	Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC). <i>Cancer Research</i> , 2022, 82, P5-16-11-P5-16-11.	0.9	1
232	Abstract PD10-04: Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC). <i>Cancer Research</i> , 2022, 82, PD10-04-PD10-04.	0.9	1
233	The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study. <i>Cancer Medicine</i> , 2022, 11, 705-714.	2.8	1
234	A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS611-TPS611.	1.6	1

#	ARTICLE	IF	CITATIONS
235	Quality of life on TSUâ€68: Combination of docetaxel and TSUâ€68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 365-371.	1.1	0
236	<i>Fcr3A</i>-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. <i>Journal of Breast Cancer</i> , 2018, 21, 45.	1.9	0
237	Data on distant metastasis and survival after locoregional recurrence following nipple-sparing mastectomy and immediate breast reconstruction. <i>Data in Brief</i> , 2021, 35, 106837.	1.0	0
238	Impact of Local Breast Cancer Recurrence on Reconstructed Breast in Nipple-Sparing Mastectomy with Immediate Reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021, , .	1.0	0
239	Predictive factors of no response during neoadjuvant chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11508-e11508.	1.6	0
240	Stage, biology, and age.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11512-e11512.	1.6	0
241	Comparison of concurrent chemoradiation therapy with 3-weekly versus weekly cisplatin in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II noninferiority trial (KCSG-HN10-02).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6023-6023.	1.6	0
242	Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 499-507.	3.0	0
243	A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3111-TPS3111.	1.6	0
244	Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10117-10117.	1.6	0
245	Prognostic stratification of locoregional esophageal cancer (EC) patients (pts) treated with definitive chemoradiotherapy (dCRT).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15578-e15578.	1.6	0
246	Abstract P5-13-36: Germline <i>BRCA</i>1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. <i>Cancer Research</i> , 2022, 82, P5-13-36-P5-13-36.	0.9	0
247	Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16107-e16107.	1.6	0
248	Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16095-e16095.	1.6	0